Clinical trials located in

Rozzano

Rozzano city is located in Italy. Currently, 20 clinical trials are being conducted in this city.

Rozzano, located in the Metropolitan City of Milan, Italy, is a city rich in history and culture. Established during the Roman era, it has evolved from an agricultural village into a modern urban center. Rozzano is home to the remarkable 15th-century Visconteo Castle, showcasing medieval architecture. The city also hosts the impressive Fiordaliso, one of Italy’s largest shopping centers. Additionally, Rozzano is known for its green spaces, including the South Milan Agricultural Park, blending nature with urban life.

  • CT-EU-00121743

    Study comparing Giredestrant and Fulvestrant with CDK4/6 Inhibitors for advanced breast cancer

    This study focuses on a type of advanced breast cancer known as Estrogen Receptor-Positive (ER+), HER2-Negative breast cancer. This kind of cancer is driven by hormones and does not have high levels of the HER2 protein. The study aims to evaluate the effectiveness and safety of a new drug called Giredestrant compared to an existing drug called Fulvestrant. Both drugs will be combined with one of three medicines that inhibit proteins in cancer cells called CDK4/6 inhibitors (Palbociclib, Ribociclib, or Abemaciclib).

    In this study, participants will be randomly assigned to one of two groups. One group will receive Giredestrant and the other will receive Fulvestrant. Both groups will also receive one of the CDK4/6 inhibitors chosen by their doctor. These combinations are being tested to see which works better to stop the cancer from growing or spreading.

    The drugs involved include Giredestrant (RO7197597, RG6171, GDC-9545), Fulvestrant, Abemaciclib, Palbociclib, Ribociclib, and LHRH Agonist (for pre/perimenopausal women and men).

    The goal is to find out if Giredestrant can provide better results and fewer side effects compared to Fulvestrant when both are combined with one of the CDK4/6 inhibitors. The study may involve regular tests and assessments to monitor the cancer’s progress and the patient’s response to the treatment.

    Participants will continue to receive the study drugs as long as they are benefiting from them and not experiencing unacceptable side effects. The study involves close monitoring to ensure the safety and well-being of all participants throughout the treatment period.

    • LHRH Agonist
    • Abemaciclib
    • Giredestrant
    • Palbociclib
    • Ribociclib
    • Fulvestrant
  • CT-EU-00068410

    A study of the treatment of advanced breast cancer with Giredestrant and the drug combination Phesgo

    The study is aimed at patients with locally advanced or metastatic breast cancer that is HER2-positive and ER-positive. HER2 and ER are receptors that can influence the growth of cancer cells. The aim of this study is to evaluate the effectiveness and safety of the combination of giredestrant and Phesgo compared with Phesgo alone after a run-in phase with Phaesgo and taxane-based chemotherapy.

    Phesgo is a combination containing pertuzumab, trastuzumab and hyaluronidase, administered subcutaneously every three weeks. Giredestrant is a capsule taken orally every day. Taxane chemotherapy may include drugs such as Docetaxel and Paclitaxel, which are given intravenously. The aim of the study is to compare how well these drug combinations work in preventing disease progression and improving patient survival.

    • hyaluronidase
    • Giredestrant
    • Pertuzumab
    • Trastuzumab
    • Paclitaxel
    • Docetaxel
  • Study of Palazestrant or standard therapy in advanced ER+/HER2- breast cancer

    This clinical trial is for patients with advanced or metastatic breast cancer with hyperactivity of estrogen receptors (ER+) and no hyperactivity of HER2- receptors (advanced HER2- breast cancer). The therapy used in the study includes a new drug called palazestrant (OP-1250) and other standard endocrine therapies such as Fulvestrant or aromatase inhibitors (anastrozole, letrozole, exemestane).

    The aim of the study is to compare the effectiveness and safety of palazestrant (OP-1250) as monotherapy compared to the above-mentioned standard therapies in the treatment of this type of breast cancer.

    Patients in the study will be randomly assigned to one of the groups – one receiving palazestrant (OP-1250) and the other receiving one of the standard therapies (fulvestrant, anastrozole, letrozole or exemestane). The study will assess progression-free survival (the time from the start of treatment to the time the disease starts to progress again) and overall survival of participants (the time from the start of treatment to death from any cause).

    • Palazestrant
    • Fulvestrant
    • Anastrozole
    • Letrozole
    • Exemestane
  • Study on the use of Volixibat for the treatment of pruritus in patients with primary cholangitis (PBC)

    The purpose of this clinical trial is to evaluate the efficacy and safety of an investigational drug called volixibat in patients with pruritus caused by primary cholangitis. The study aims to understand how volixibat affects the treatment of pruritus associated with this disease and to evaluate its possible effect on disease progression.

    Study participants will be randomly assigned to a group receiving volixibat or placebo. Volixibat will be administered as oral capsules twice daily. The main goal of the study is to measure the average change in daily pruritus scores using a special Adult Itch Reported Outcome (Adult ItchRO) questionnaire. Adult ItchRO is an 11-point scale for assessing pruritus severity, where 0 means no pruritus and 10 means the worst possible pruritus. The study will run from baseline to week 28.

    • Volixibat
    • Placebo
  • A study of dupilumab in the treatment of Eosinophilic gastroenteritis in adults and adolescents

    The study involves a drug called Dupilumab and targets adults and adolescents with active eosinophilic gastroenteritis. This is a rare chronic immune disease in which eosinophils (a type of white blood cell) accumulate in large numbers in the stomach and small intestine, causing inflammation and damage. The aim of the study is to evaluate the effect of dupilumab on relieving symptoms of the disease and reducing inflammation in the stomach and small intestine in adults and adolescents.

    The study consists of three parts, plus a screening and observation part. In Parts A and B, participants will be randomly assigned to a group receiving dupilumab or placebo for 24 weeks in a double-blind (neither participants, physicians nor study staff will know which treatment a participant is receiving). Part C is a 28-week extension part, in which all participants from parts A and B will receive dupilumab.

    • Placebo
    • Dupilumab
  • Study of Barzolvolimab (CDX-0159) in Adult Patients with Eosinophilic Esophagitis

    This clinical study involves patients with Eosinophilic Esophagitis (EoE), a condition where a type of white blood cell, called eosinophils, builds up in the lining of the esophagus. This can lead to difficulty swallowing and other issues. The therapy being tested is barzolvolimab (CDX-0159).

    The goal of the study is to test the effectiveness and safety of barzolvolimab in adults with active EoE. There are two main groups in this study: one will receive barzolvolimab, and the other will receive a placebo, followed by barzolvolimab.

    Participants will receive treatment through subcutaneous (under the skin) injections every four weeks for 24 weeks. In the barzolvolimab group, patients will get 300 mg of the medication from the start. In the other group, patients will receive a placebo for the first 16 weeks and then switch to barzolvolimab for the remaining 8 weeks.

    The study will look at changes in the number of eosinophils and other cells in the esophagus, as well as symptoms like difficulty swallowing. Side effects and other health changes will be monitored throughout the study.

    • Placebo
    • barzolvolimab
  • Study on CRN04894 for congenital adrenal hyperplasia safety and effectiveness

    The study is designed to explore the effects of a new medication called CRN04894 on individuals who have a condition known as classic congenital adrenal hyperplasia (CAH), which is caused by a deficiency in the enzyme 21-hydroxylase. This condition affects the adrenal glands and can lead to various health issues. The main goal of this study is to understand how safe and effective CRN04894 is for people with CAH, as well as to learn how the body processes the medication.

    CRN04894 is a unique medication that is taken orally and works by blocking certain receptors in the body related to the production of adrenal hormones. By participating in this study, individuals will receive this medication for 12 weeks. During this time, researchers will closely monitor participants to see how well the medication works in reducing levels of a hormone called androstenedione, which is often elevated in people with CAH. Additionally, the study will keep track of any side effects that participants may experience to ensure the medication is safe to use.

    • CRN04894
  • Discovery of sorafenib and paclitaxel in the treatment of advanced adrenal cancer

    This clinical trial is focused on patients with Adrenocortical Carcinoma (ACC), a type of cancer that affects the adrenal glands. If a patient has ACC that has spread or cannot be removed by surgery, and if previous chemotherapy treatments haven’t worked, this study might be an option for them. The trial is testing a combination of two treatments: Sorafenib and Paclitaxel. Sorafenib is a pill taken twice a day, and Paclitaxel is given through an IV once a week. The goal is to see if this combination can help stop the cancer from growing.

    The main thing the doctors are looking to find out is if the cancer stops progressing in the first 4 months of treatment. They’re also interested in how long the treatment works, how it impacts the cancer, and any side effects that might be experienced. Another important part of the study is looking at how the treatment impacts the patient’s quality of life.

    The patient’s health will be closely monitored throughout the study, with the first check-up after 8 weeks and then every 12 weeks. This trial is a chance to try a new treatment combination that’s designed specifically for ACC patients who need more options.

    • Sorafenib
    • Paclitaxel
  • Testing a new drug for advanced prostate cancer

    This trial compares a new drug called AZD5305 with a placebo in men who have a specific kind of prostate cancer that has not responded to usual treatment methods. It’s a large trial, with around 1800 participants, and the main aim is to see whether the new treatment can help slow down the disease for longer than current treatments. Participants will be assigned to two different groups, and they will not know whether they’re receiving the real drug or the placebo. Their health will be monitored closely, with regular scans to check the progress of the cancer. The trial will also look at any side effects of the treatment and how it affects the patients’ ability to do their daily activities.

    • Enzalutamide/Xtandi
    • Darolutamide/Nubequa
    • Abiraterone Acetate/Zytiga
    • Saruparib
  • Research to enhance cancer treatments for kids and teens

    This clinical trial, known as CAMPFIRE, encompasses several studies testing new drugs for children and young adults with cancer. It includes various drug combinations such as Ramucirumab, Cyclophosphamide, Vinorelbine, Gemcitabine, Docetaxel, Abemaciclib, Irinotecan, and Temozolomide. These trials aim to evaluate the safety and effectiveness of these drugs in treating different cancer types. The study is interventional, with an estimated enrollment of 105 participants, randomized in parallel assignment. The primary purpose is treatment-focused.

    • Abemaciclib
    • Temozolomide
    • Irinotecan
    • Ramucirumab
    • Gemcitabine
    • Vinorelbine
    • Cyclophosphamide
    • Docetaxel
  • Extended safety study for participants using spartalizumab alone or combined

    This study relates to a type of medication called spartalizumab. The goal is to find out if this medicine, when given alone or with other treatments, is safe and doesn’t cause any unwanted side effects. The study is open to people who have already been involved in past studies for spartalizumab. The reason for this is to keep giving these people access to the treatment while also continuously assessing its safety.

    • spartalizumab/PDR001
  • Testing the effectiveness of new drugs in the treatment of age-related macular degeneration

    The study is investigating a potential breakthrough in treating age-related vision loss, specifically neovascular age-related macular degeneration (nAMD). It introduces a novel therapy, OPT-302, and pairs it with Aflibercept, comparing this combination’s effectiveness against the standard treatment. Participants undergo a series of thorough eye examinations and treatments to monitor the progression of their vision health. The research aims to offer a clearer understanding of how these treatments can better manage and possibly improve vision for individuals dealing with nAMD, contributing valuable knowledge to the field of eye health care.

    • aflibercept
    • OPT-302
  • Treatment of lung cancer before and after surgery using various drug combinations

    The NeoCOAST-2 trial is a phase II study evaluating various combinations of anticancer therapies in patients with resectable early-stage non-small cell lung cancer. This study is divided into two stages. The first stage occurs before surgery (neoadjuvant treatment), the next stage after surgery (adjuvant treatment). Researchers will use a drug called Durvalumab, which will be combined with various drugs. The goal is to determine the safety and effectiveness of these regimens for treating early-stage lung cancer, potentially improving treatment outcomes.

    The first group of patients will receive Oleclumab, Durvalumab and a strong drug – Carboplatin/Paclitaxel Pemetrexed/Cisplatin Pemetrexed/Carboplatin. After surgery, they will be given Oleclumab and Durvalumab.

    Patients in the second group will receive Monalizumab, Durvalumab and drugs combined with platinum before surgery. After surgery, they will be given Monalizumab and Durvalumab.

    In the third group, MEDI5752 and drugs combined with platinum are administered before surgery. After surgery, patients will only receive MEDI5752.

    People from group four receive Dato-DXd, Durvalumab, Carboplatin or Cisplatin before surgery. After surgery, they will be given Durvalumab.

    Participants in the fifth group will receive AZD0171, Durvalumab and platinum doublet chemotherapy before surgery. After surgery, patients will receive AZD0171 and Durvalumab.

    • AZD0171- new potential medication for advanced cancer
    • Oleclumab
    • Monalizumab
    • MEDI5752
    • Dato-DXd
    • Pemetrexed
    • Paclitaxel
    • Cisplatin
    • Carboplatin
    • Durvalumab
  • Glofitamab and obinutuzumab: new treatment study for Non-Hodgkin’s lymphoma

    In this study, researchers are trying to learn more about a new drug treatment for B-cell Non-Hodgkin’s Lymphoma – a type of blood cancer. The study is happening in many places and is open for patients who have not had success with their previous treatments. The new drug, called glofitamab, will be given to these patients. The amount of glofitamab will be slowly raised to ensure it’s safe. Another drug, obinutuzumab, will be used with glofitamab. The study will go in 3 steps. For the first two steps, the quantity of glofitamab will be increased slowly. When the safest large dose is found, this medicine will be given to more people in the last step.

    • Tocilizumab
    • Obinutuzumab
    • Glofitamab
  • Trial for high-risk Lymphoma Patients comparing Axicabtagene Ciloleucel and standard therapy

    In this study, the researchers are trying to find out if a new drug called Axicabtagene Ciloleucel is a better first treatment for a type of blood cancer known as high-risk large B-cell lymphoma, compared to the current standard treatment. This is a big study, done in many places, where patients will be randomly picked to get either the new drug or the current standard treatment. Five years after the last patient joins the study, those who had the new drug will join another study to see how they are doing for the next 10 years. The study will look at a few things, like how long until the disease gets worse, how many people’s cancer has gone away after the treatment, and how their quality of life and health status are, using different questionnaires.

    • Axicabtagene Ciloleucel
    • Prednisone
    • Fludarabine
    • Vincristine
    • Doxorubicin
    • Etoposide
    • Cyclophosphamide
    • Rituximab
  • Ceralasertib & durvalumab vs docetaxel in advanced lung cancer study

    This is an open-label study titled LATIFY, which means everyone will know the type of treatment they are receiving. The study team is looking into a specific type of lung cancer, called Non-Small Cell Lung Cancer (NSCLC) which did not get better after previous treatments. Two treatments will be tested, a new combination of ceralasertib plus durvalumab, compared to a commonly used treatment, docetaxel. Doctors will track participants’ health over time to see which treatment helps people live longer. Understanding the results will help doctors responsibly give the best treatment for patients with this type of lung cancer.

    • Ceralasertib
    • Durvalumab
    • Docetaxel
  • Understanding biliary tract cancer treatment with rilvegostomig and chemotherapy

    This study focuses on a new treatment for biliary tract cancer using the drug rilvegostomig combined with chemotherapy. It is for patients who have had surgery to remove this cancer. The study will compare the effectiveness of rilvegostomig with a placebo in combination with investigator’s choice of chemotherapy options like capecitabine, gemcitabine/cisplatin, or S-1. The main aim is to see if this new treatment can prevent cancer from coming back. About 750 people will take part in this global study, which is in the final phase of testing.

    • Gimeracil
    • Oteracil
    • Tegafur
    • Gemcitabine
    • Cisplatin
    • Rilvegostomig
    • Capecitabine
  • Evaluating efinopegdutide treatment for nonalcoholic steatohepatitis

    This clinical trial explores a new treatment for non-alcoholic steatohepatitis (NASH), a liver condition. It tests the safety and effectiveness of efinopegdutide, a medication administered through weekly injections. Participants, diagnosed with NASH but not severe liver damage, will receive either the medication or a placebo. The study aims to improve liver health and assess potential side effects. It prioritizes participant safety and involves regular health monitoring.

    • Efinopegdutide
    • Semaglutide
  • Trial on new immune therapies for advanced liver and bile duct cancer

    This study is for people with advanced cancers in the liver and biliary system. The main purpose of the study is to test the effectiveness and safety of new drugs that work with the body’s immune system. These drugs can be used by themselves or with other anti-cancer drugs. The study is separated into two parts. In the first part, around 120 participants with advanced liver cancer will be given MEDI5752 (volrustomig) by itself or with bevacizumab or lenvatinib. The second part involves about 60 participants with advanced bile duct cancer (that haven’t been treated) who will be given AZD2936 or MEDI5752 along with gemcitabine and cisplatin.

    • MEDI5752 (Volrustomig)
    • Rilvegostomig
    • Lenvatinib
    • Bevacizumab
    • Gemcitabine
    • Cisplatin
  • Improving psoriasis treatment for patients: a study on brodalumab

    This detailed study focuses on individuals with moderate-to-severe plaque psoriasis who weigh more than 120 kg. It aims to find out if adjusting the dose of the medication brodalumab can lead to better skin health. In this study, participants receive either an adjusted higher dose of brodalumab or the standard dose. Researchers closely monitor the skin’s response to the treatment, checking if the adjusted dose leads to better skin clearance, meaning fewer or no psoriasis symptoms.

    • Brodalumab

See more clinical trials in other cities in Italy:

.